A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo

M. L. Alegre, L. J. Peterson, D. Xu, H. A. Sattar, D. R. Jeyarajah, K. Kowalkowski, J. R. Thistlethwaite, R. A. Zivin, L. Jolliffe, J. A. Bluestone

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

OKT3, a mouse anti-human CD3 mAb, is a potent immunosuppressive agent used in clinical transplantation to prevent or treat allograft rejection. Associated with this therapy is the systemic release of several cytokines that result in a series of adverse side effects. This release of cytokines is dependent on the cross-linking mediated by OKT3 between T cells and the FcγR-bearing cells. To generate an anti-human CD3 mAb with reduced activating properties as compared with OKT3, we have transferred the complementary determining regions of OKT3 onto human IgG frameworks and then performed point mutations that reduce the affinity of the 'humanized' anti- CD3 mAbs for FcγRs. Initial, in vitro, studies showed that whereas OKT3 and the parental humanized anti-CD3 mAbs activated T cells similarly, a humanized Fc variant failed to do so. Both the Fc variant and the activating anti-CD3 mAbs induced comparable modulation of the TCR and suppression of cytolytic T cell activity, in vitro. In the current study, we exploited an experimental model in which human splenocytes from cadaveric organ donors were inoculated into severe combined immunodeficient mice (hu-SPL-SCID mice) to test the activating and immunosuppressive properties of these anti-human CD3 mAbs in vivo. Unlike injection of OKT3 or of the parental humanized mAb, administration of the Fc variant did not result in T cell activation in vivo, as evidenced by the lack of induction of surface markers of activation, and of systemic human cytokines, including IL-2. Importantly, similar prolongation of human allograft survival was achieved with all anti-CD3 mAbs, indicating that the nonactivating anti-CD3 mAbs retained significant immunosuppressive properties in vivo. Thus, the use of an Fc variant in clinical transplantation should result in fewer side effects than observed with OKT3, while maintaining its clinical efficacy.

Original languageEnglish
Pages (from-to)1537-1543
Number of pages7
JournalTransplantation
Volume57
Issue number11
StatePublished - Jan 1 1994

Fingerprint

Muromonab-CD3
Immunosuppressive Agents
Monoclonal Antibodies
T-Lymphocytes
SCID Mice
Cytokines
Allografts
Transplantation
Point Mutation
Interleukin-2
Theoretical Models
Immunoglobulin G
Tissue Donors
Injections

ASJC Scopus subject areas

  • Immunology
  • Transplantation

Cite this

Alegre, M. L., Peterson, L. J., Xu, D., Sattar, H. A., Jeyarajah, D. R., Kowalkowski, K., ... Bluestone, J. A. (1994). A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation, 57(11), 1537-1543.

A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. / Alegre, M. L.; Peterson, L. J.; Xu, D.; Sattar, H. A.; Jeyarajah, D. R.; Kowalkowski, K.; Thistlethwaite, J. R.; Zivin, R. A.; Jolliffe, L.; Bluestone, J. A.

In: Transplantation, Vol. 57, No. 11, 01.01.1994, p. 1537-1543.

Research output: Contribution to journalArticle

Alegre, ML, Peterson, LJ, Xu, D, Sattar, HA, Jeyarajah, DR, Kowalkowski, K, Thistlethwaite, JR, Zivin, RA, Jolliffe, L & Bluestone, JA 1994, 'A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo', Transplantation, vol. 57, no. 11, pp. 1537-1543.
Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K et al. A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 1994 Jan 1;57(11):1537-1543.
Alegre, M. L. ; Peterson, L. J. ; Xu, D. ; Sattar, H. A. ; Jeyarajah, D. R. ; Kowalkowski, K. ; Thistlethwaite, J. R. ; Zivin, R. A. ; Jolliffe, L. ; Bluestone, J. A. / A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. In: Transplantation. 1994 ; Vol. 57, No. 11. pp. 1537-1543.
@article{c4f74321b46f4101a291a54b4eff3528,
title = "A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo",
abstract = "OKT3, a mouse anti-human CD3 mAb, is a potent immunosuppressive agent used in clinical transplantation to prevent or treat allograft rejection. Associated with this therapy is the systemic release of several cytokines that result in a series of adverse side effects. This release of cytokines is dependent on the cross-linking mediated by OKT3 between T cells and the FcγR-bearing cells. To generate an anti-human CD3 mAb with reduced activating properties as compared with OKT3, we have transferred the complementary determining regions of OKT3 onto human IgG frameworks and then performed point mutations that reduce the affinity of the 'humanized' anti- CD3 mAbs for FcγRs. Initial, in vitro, studies showed that whereas OKT3 and the parental humanized anti-CD3 mAbs activated T cells similarly, a humanized Fc variant failed to do so. Both the Fc variant and the activating anti-CD3 mAbs induced comparable modulation of the TCR and suppression of cytolytic T cell activity, in vitro. In the current study, we exploited an experimental model in which human splenocytes from cadaveric organ donors were inoculated into severe combined immunodeficient mice (hu-SPL-SCID mice) to test the activating and immunosuppressive properties of these anti-human CD3 mAbs in vivo. Unlike injection of OKT3 or of the parental humanized mAb, administration of the Fc variant did not result in T cell activation in vivo, as evidenced by the lack of induction of surface markers of activation, and of systemic human cytokines, including IL-2. Importantly, similar prolongation of human allograft survival was achieved with all anti-CD3 mAbs, indicating that the nonactivating anti-CD3 mAbs retained significant immunosuppressive properties in vivo. Thus, the use of an Fc variant in clinical transplantation should result in fewer side effects than observed with OKT3, while maintaining its clinical efficacy.",
author = "Alegre, {M. L.} and Peterson, {L. J.} and D. Xu and Sattar, {H. A.} and Jeyarajah, {D. R.} and K. Kowalkowski and Thistlethwaite, {J. R.} and Zivin, {R. A.} and L. Jolliffe and Bluestone, {J. A.}",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "57",
pages = "1537--1543",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo

AU - Alegre, M. L.

AU - Peterson, L. J.

AU - Xu, D.

AU - Sattar, H. A.

AU - Jeyarajah, D. R.

AU - Kowalkowski, K.

AU - Thistlethwaite, J. R.

AU - Zivin, R. A.

AU - Jolliffe, L.

AU - Bluestone, J. A.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - OKT3, a mouse anti-human CD3 mAb, is a potent immunosuppressive agent used in clinical transplantation to prevent or treat allograft rejection. Associated with this therapy is the systemic release of several cytokines that result in a series of adverse side effects. This release of cytokines is dependent on the cross-linking mediated by OKT3 between T cells and the FcγR-bearing cells. To generate an anti-human CD3 mAb with reduced activating properties as compared with OKT3, we have transferred the complementary determining regions of OKT3 onto human IgG frameworks and then performed point mutations that reduce the affinity of the 'humanized' anti- CD3 mAbs for FcγRs. Initial, in vitro, studies showed that whereas OKT3 and the parental humanized anti-CD3 mAbs activated T cells similarly, a humanized Fc variant failed to do so. Both the Fc variant and the activating anti-CD3 mAbs induced comparable modulation of the TCR and suppression of cytolytic T cell activity, in vitro. In the current study, we exploited an experimental model in which human splenocytes from cadaveric organ donors were inoculated into severe combined immunodeficient mice (hu-SPL-SCID mice) to test the activating and immunosuppressive properties of these anti-human CD3 mAbs in vivo. Unlike injection of OKT3 or of the parental humanized mAb, administration of the Fc variant did not result in T cell activation in vivo, as evidenced by the lack of induction of surface markers of activation, and of systemic human cytokines, including IL-2. Importantly, similar prolongation of human allograft survival was achieved with all anti-CD3 mAbs, indicating that the nonactivating anti-CD3 mAbs retained significant immunosuppressive properties in vivo. Thus, the use of an Fc variant in clinical transplantation should result in fewer side effects than observed with OKT3, while maintaining its clinical efficacy.

AB - OKT3, a mouse anti-human CD3 mAb, is a potent immunosuppressive agent used in clinical transplantation to prevent or treat allograft rejection. Associated with this therapy is the systemic release of several cytokines that result in a series of adverse side effects. This release of cytokines is dependent on the cross-linking mediated by OKT3 between T cells and the FcγR-bearing cells. To generate an anti-human CD3 mAb with reduced activating properties as compared with OKT3, we have transferred the complementary determining regions of OKT3 onto human IgG frameworks and then performed point mutations that reduce the affinity of the 'humanized' anti- CD3 mAbs for FcγRs. Initial, in vitro, studies showed that whereas OKT3 and the parental humanized anti-CD3 mAbs activated T cells similarly, a humanized Fc variant failed to do so. Both the Fc variant and the activating anti-CD3 mAbs induced comparable modulation of the TCR and suppression of cytolytic T cell activity, in vitro. In the current study, we exploited an experimental model in which human splenocytes from cadaveric organ donors were inoculated into severe combined immunodeficient mice (hu-SPL-SCID mice) to test the activating and immunosuppressive properties of these anti-human CD3 mAbs in vivo. Unlike injection of OKT3 or of the parental humanized mAb, administration of the Fc variant did not result in T cell activation in vivo, as evidenced by the lack of induction of surface markers of activation, and of systemic human cytokines, including IL-2. Importantly, similar prolongation of human allograft survival was achieved with all anti-CD3 mAbs, indicating that the nonactivating anti-CD3 mAbs retained significant immunosuppressive properties in vivo. Thus, the use of an Fc variant in clinical transplantation should result in fewer side effects than observed with OKT3, while maintaining its clinical efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0028178492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028178492&partnerID=8YFLogxK

M3 - Article

C2 - 8009586

AN - SCOPUS:0028178492

VL - 57

SP - 1537

EP - 1543

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 11

ER -